ANXA9 As a Novel Prognostic Biomarker Associated with Immune Infiltrates in Gastric Cancer

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2022 Jan 10

PMID 35003923

Authors

Tongtong Zhang

Suyang Yu

Shipeng Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Gastric cancer (GC) is the most prevalent malignancy among the digestive system tumors. Increasing evidence has revealed that lower mRNA expression of ANXA9 is associated with a poor prognosis in colorectal cancer. However, the role of ANXA9 in GC remains largely unknown.

Material And Methods: The Gene Expression Profiling Interactive Analysis (GEPIA) and Human Protein Atlas databases were used to investigate the expression of ANXA9 in GC, which was then validated in the four Gene Expression Omnibus (GEO) datasets. The diagnostic value of ANXA9 for GC patients was demonstrated using a receiver operating characteristic (ROC) curve. The correlation between ANXA9 expression and clinicopathological parameters was analyzed in The Cancer Genome Atlas (TCGA) and UALCAN databases. The Kaplan-Meier (K-M) survival curve was used to elucidate the relationship between ANXA9 expression and the survival time of GC patients. We then performed a gene set enrichment analysis (GSEA) to explore the biological functions of ANXA9. The relationship of ANXA9 expression and cancer immune infiltrates was analyzed using the Tumor Immune Estimation Resource (TIMER). In addition, the potential mechanism of ANXA9 in GC was investigated by analyzing its related genes.

Results: ANXA9 was significantly up-regulated in GC tissues and showed obvious diagnostic value. The expression of ANXA9 was related to the age, gender, grade, TP53 mutation, and histological subtype of GC patients. We also found that ANXA9 expression was associated with immune-related biological function. ANXA9 expression was also correlated with the infiltration level of CD8 T cells, neutrophils, and dendritic cells in GC. Additionally, copy number variation (VNV) of ANXA9 occurred in GC patients. Function enrichment analyses revealed that ANXA9 plays a role in the GC progression by interacting with its related genes.

Conclusions: Our results provide strong evidence of ANXA9 expression as a prognostic indicator related to immune responses in GC.

Citing Articles

Human sulfotransferase physiological role and the impact of genetic polymorphism on enzyme activity and pathological conditions.

Alherz F Front Genet. 2024; 15:1464243.

PMID: 39280099 PMC: 11392796. DOI: 10.3389/fgene.2024.1464243.

ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.

Zhou X, Zhao J, Yan T, Ye D, Wang Y, Zhou B Cell Death Dis. 2024; 15(4):260.

PMID: 38609357 PMC: 11014919. DOI: 10.1038/s41419-024-06643-4.

Annexin A9 promotes cell proliferation by regulating the Wnt signaling pathway in colorectal cancer.

Lu X, Hu L, Mao J, Zhang S, Cai Y, Chen W Hum Cell. 2023; 36(5):1729-1740.

PMID: 37349657 PMC: 10390359. DOI: 10.1007/s13577-023-00939-x.

Harmine loaded Au@MSNs@PEG@Asp6 nano-composites for treatment of spinal metastasis from lung adenocarcinoma by targeting ANXA9 experiment.

Wang H, Chen F, Hu A, Liang H, Liang Y, Seetharamu N Transl Lung Cancer Res. 2023; 12(5):1062-1077.

PMID: 37323183 PMC: 10261857. DOI: 10.21037/tlcr-23-191.

Exosome-derived ANXA9 functions as an oncogene in breast cancer.

Lu C, Zhan Y, Jiang Y, Liao J, Qiu Z J Pathol Clin Res. 2023; 9(5):378-390.

PMID: 37294149 PMC: 10397375. DOI: 10.1002/cjp2.334.

References

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Nguyen D, Hoang D, Nguyen Vo T, Huynh V, Ghoda L, Marcucci G . The role of ErbB3 binding protein 1 in cancer: Friend or foe?. J Cell Physiol. 2018; 233(12):9110-9120. DOI: 10.1002/jcp.26951. View

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

Kataoka T, Ito A, Asada H, Watabe K, Nishiyama K, Nakamoto K . Annexin VII as a novel marker for invasive phenotype of malignant melanoma. Jpn J Cancer Res. 2000; 91(1):75-83. PMC: 5926233. DOI: 10.1111/j.1349-7006.2000.tb00862.x. View

Kim C, Mulder K, Spratlin J . How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist. 2014; 19(10):1046-55. PMC: 4201005. DOI: 10.1634/theoncologist.2014-0006. View

Li S, Zeng F, Li J, Shu Q, Zhang H, Xu J . Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1. Cancer Lett. 2018; 431:43-53. DOI: 10.1016/j.canlet.2018.05.032. View

Cao R, Yuan L, Ma B, Wang G, Tian Y . Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA). Cancer Cell Int. 2020; 20:276. PMC: 7320553. DOI: 10.1186/s12935-020-01362-0. View

Georg Luebeck E, Curtius K, Jeon J, Hazelton W . Impact of tumor progression on cancer incidence curves. Cancer Res. 2012; 73(3):1086-96. PMC: 3746830. DOI: 10.1158/0008-5472.CAN-12-2198. View

Lordick F, Kang Y, Chung H, Salman P, Oh S, Bodoky G . Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013; 14(6):490-9. DOI: 10.1016/S1470-2045(13)70102-5. View

10.

Asplund A, Edqvist P, Schwenk J, Ponten F . Antibodies for profiling the human proteome-The Human Protein Atlas as a resource for cancer research. Proteomics. 2012; 12(13):2067-77. DOI: 10.1002/pmic.201100504. View

11.

Goebeler V, Ruhe D, Gerke V, Rescher U . Atypical properties displayed by annexin A9, a novel member of the annexin family of Ca(2+) and lipid binding proteins. FEBS Lett. 2003; 546(2-3):359-64. DOI: 10.1016/s0014-5793(03)00634-3. View

12.

Maeder M, Angstman J, Richardson M, Linder S, Cascio V, Tsai S . Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat Biotechnol. 2013; 31(12):1137-42. PMC: 3858462. DOI: 10.1038/nbt.2726. View

13.

Yu S, Bian H, Gao X, Gui L . Annexin A9 promotes invasion and metastasis of colorectal cancer and predicts poor prognosis. Int J Mol Med. 2018; 41(4):2185-2192. DOI: 10.3892/ijmm.2018.3432. View

14.

Maeda K, Chung Y, Ogawa Y, Takatsuka S, Kang S, Ogawa M . Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996; 77(5):858-63. DOI: 10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a. View

15.

Correa P . Gastric cancer: overview. Gastroenterol Clin North Am. 2013; 42(2):211-7. PMC: 3995345. DOI: 10.1016/j.gtc.2013.01.002. View

16.

Smid M, Wang Y, Klijn J, Sieuwerts A, Zhang Y, Atkins D . Genes associated with breast cancer metastatic to bone. J Clin Oncol. 2006; 24(15):2261-7. DOI: 10.1200/JCO.2005.03.8802. View

17.

Srivastava M, Bubendorf L, Raffeld M, Bucher C, Torhorst J, Sauter G . Prognostic impact of ANX7-GTPase in metastatic and HER2-negative breast cancer patients. Clin Cancer Res. 2004; 10(7):2344-50. DOI: 10.1158/1078-0432.ccr-03-0278. View

18.

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

19.

Salom C, Alvarez-Teijeiro S, Fernandez M, Morgan R, Allonca E, Vallina A . Frequent Alteration of Annexin A9 and A10 in HPV-Negative Head and Neck Squamous Cell Carcinomas: Correlation with the Histopathological Differentiation Grade. J Clin Med. 2019; 8(2). PMC: 6406441. DOI: 10.3390/jcm8020229. View

20.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View